Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $240.0 million.

  • Assembly Biosciences' Liabilities and Shareholders Equity rose 139.37% to $240.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 14.12%. This contributed to the annual value of $119.2 million for FY2024, which is 12.90% down from last year.
  • Assembly Biosciences' Liabilities and Shareholders Equity amounted to $240.0 million in Q3 2025, which was up 197.10% from $80.8 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Liabilities and Shareholders Equity high stood at $278.9 million for Q1 2021, and its period low was $51.6 million during Q3 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $100.3 million (2024), whereas its average is $110.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 57.51% in 2023, then soared by 139.37% in 2025.
  • Quarterly analysis of 5 years shows Assembly Biosciences' Liabilities and Shareholders Equity stood at $191.1 million in 2021, then slumped by 46.72% to $101.8 million in 2022, then surged by 34.41% to $136.8 million in 2023, then dropped by 12.90% to $119.2 million in 2024, then soared by 139.37% to $240.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $240.0 million in Q3 2025, compared to $80.8 million in Q2 2025 and $99.0 million in Q1 2025.